nach oben

Cancer Causes & Control

Erschienen in:

05.06.2021 | Original Paper

Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity

verfasst von: Maira A. Castañeda-Avila, Bill M. Jesdale, Ariel Beccia, Ganga S. Bey, Mara M. Epstein

Erschienen in: Cancer Causes & Control | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We examined the combined influences of race/ethnicity and neighborhood socioeconomic status (SES) on long-term survival among patients with multiple myeloma (MM).

Methods

Data from the 2000–2015 NCI Surveillance, Epidemiology, and End Results Program (SEER-18) were used. Census tract-level SES index was assessed in tertiles (low, medium, high SES). Competing-risk modeling was used to estimate sub-hazard ratios (SHR) and 95% confidence intervals (CIs) for SES tertile adjusted for sex and age at diagnosis and stratified by race/ethnicity.

Results

Overall, living in a low SES neighborhood was associated with worse MM survival. However, we observed some variation in the association by racial/ethnic group. Living in a low versus a high SES neighborhood was associated with a 35% (95% CI = 1.16–1.57) increase in MM-specific mortality risk among Asian/Pacific Islander cases, a 17% (95% CI = 1.12–1.22) increase among White cases, a 14% (95% CI = 1.04–1.23) increase among Black cases, and a 7% (95% CI = 0.96–1.19) increase among Hispanic cases.

Conclusion

These results suggest that the influence of both SES and race/ethnicity should be considered when considering interventions to remedy disparities in MM survival.

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129CrossRefPubMedPubMedCentral

Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE (2017) Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv 1(4):282–287. https://doi.org/10.1182/bloodadvances.2016002493CrossRefPubMedPubMedCentral

Pulte D, Redaniel MT, Brenner H, Jansen L, Jeffreys M (2014) Recent improvement in survival of patients with multiple myeloma: Variation by ethnicity. Leuk Lymphoma 55(5):1083–1089. https://doi.org/10.3109/10428194.2013.827188CrossRefPubMed

Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT, Fairbanks RK, Weeks KA, Lee CM (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95:64–70. https://doi.org/10.1007/s12185-011-0971-zCrossRefPubMed

Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A (2012) Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups. Br J Haematol 158(1):91–98. https://doi.org/10.1111/j.1365-2141.2012.09124.xCrossRefPubMed

Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Jipan Xie J (2019) Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A SEER-Medicare analysis. Blood Adv 3(20):2986–2994. https://doi.org/10.1182/bloodadvances.2019000308CrossRefPubMedPubMedCentral

Anderson NB, Bulatao RA, Cohen B (2004) National research council (US) panel on race, ethnicity, and socioeconomic status, and health in later life. Critical perspectives on racial and ethnic differences in health in late life. National Academies Press (US), Washington, DC

Williams DR, Mohammed SA, Leavell J, Collins C (2010) Race, socioeconomic status, and health: Complexities, ongoing challenges, and research opportunities. Ann N Y Acad Sci 1186:69–101. https://doi.org/10.1111/j.1749-6632.2009.05339.xCrossRefPubMedPubMedCentral

10.

Williams DR, Kontos EZ, Viswanath K, Haas JS, Lathan CS, MacConaill LE, Chen J, Ayanian JZ (2012) Integrating multiple social statuses in health disparities research: The case of lung cancer. Health Serv Res 47(3 Pt 2):1255–1277. https://doi.org/10.1111/j.1475-6773.2012.01404.xCrossRefPubMedPubMedCentral

11.

Williams DR, Priest N, Anderson NB (2016) Understanding associations among race, socioeconomic status, and health: Patterns and prospects. Health Psychol 35(4):407–411. https://doi.org/10.1037/hea0000242CrossRefPubMedPubMedCentral

12.

Bowleg L (2012) The problem with the phrase women and minorities: Intersectionality-an important theoretical framework for public health. Am J Public Health 102(7):1267–1273. https://doi.org/10.2105/AJPH.2012.300750CrossRefPubMedPubMedCentral

13.

Baris D, Brown LM, Silverman DT, Hayes R, Hoover RN, Swanson GM, Dosemeci M, Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Lubin J, Greenberg RS, Fraumeni JF Jr (2000) Socioeconomic status and multiple myeloma among US Blacks and Whites. Am J Public Health 90(8):1277–1281. https://doi.org/10.2105/AJPH.90.8.1277CrossRefPubMedPubMedCentral

14.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs excluding AK (with additional treatment fields), Nov 2017 Sub (2000–2015) <Vintage 2015 Pops by Race/Origin Tract 2000/2010 Mixed Geographies> - Linked To Census Tract Attributes - Time Dependent (2000–2015) - SEER 18 (excl AK) Census 2000/2010 Geographies with Index Field Quantiles, National Cancer Institute, DCCPS, Surveillance Research Program, released June 2018, based on the November 2017 submission.

15.

Yu M, Tatalovich Z, Gibson JT, Cronin KA (2014) Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control 25(1):81–92. https://doi.org/10.1007/s10552-013-0310-1CrossRefPubMed

16.

Chen BE, Kramer JL, Greene MH, Rosenberg PS (2008) Competing risks analysis of correlated failure time data. Biometrics 64(1):172–179. https://doi.org/10.1111/j.1541-0420.2007.00868.xCrossRefPubMed

17.

Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM (2015) Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma 56(9):2643–2649. https://doi.org/10.3109/10428194.2015.1011156CrossRefPubMedPubMedCentral

18.

Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J, Faiman B, Hussein M (2006) The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 91(10):1410–1413. https://doi.org/10.3324/%25xCrossRefPubMed

19.

Manojlovic Z, Christofferson A, Liang WS, Aldrich J, Washington M, Wong S, Rohrer D, Jewell S, Kittles RA, Derome M, Auclair D, Craig DW, Keats J, Carpten JD (2017) Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLOS Genet. 13(11):e1007087CrossRef

20.

Williams DR, Sternthal M (2010) Understanding Racial-ethnic Disparities in Health: Sociological Contributions. J Health Soc Behav 51(1):S15–S27CrossRef

21.

Abdallah SN, Rajkumar V, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK (2020) Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. https://doi.org/10.1038/s41408-020-00348-5CrossRefPubMedPubMedCentral

22.

Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC (2020) Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis”. Blood Cancer J. https://doi.org/10.1038/s41408-020-00347-6CrossRefPubMedPubMedCentral

23.

Fiala MA, Keller J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM (2014) Treatment advances for multiple myeloma have disproportionally benefited patients Who are young, white, and have higher socioeconomic status. Blood 124(21):555–555CrossRef

24.

Crenshaw K (1989) Demarginalizing the intersection of race and sex: A black feminist critique of antidiscrimination doctrine, feminist theory, and antiracist politics. Univ Chic Leg Forum 140:139–167

25.

Collins PH (1990) Black Feminist Thought: Knowledge, Consciousness, and the Politics of Empowerment. Routledge, New York

26.

Bauer GR (2014) Incorporating intersectionality theory into population health research methodology: Challenges and the potential to advance health equity. Soc Sci Med 110:10–17. https://doi.org/10.1016/j.socscimed.2014.03.022CrossRefPubMed

27.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL (2019) Siegel RL (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin 69(5):363–385. https://doi.org/10.3322/caac.21565CrossRef

28.

Stepanikova I, Oates GR (2017) Perceived discrimination and privilege in health care: the role of socioeconomic status and race. Am J Prev Med 52(1):S86–S94. https://doi.org/10.1016/j.amepre.2016.09.024CrossRefPubMedPubMedCentral

29.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2020) SEER Cancer Statistics Review, 1975–2017. National Cancer Institute, Bethesda, MD

30.

Gliklich R, Dreyer N, Leavy M (2014) Analysis, Interpretation, and Reporting of Registry Data To Evaluate Outcomes. In: Gliklich RE, Dreyer NA, Leavy MB (eds) Registries for Evaluating Patient Outcomes: A User’s Guide. Agency for Healthcare Research and Quality (US), Rockville, MD, pp 1–25

Titel: Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity
verfasst von: Maira A. Castañeda-Avila
Bill M. Jesdale
Ariel Beccia
Ganga S. Bey
Mara M. Epstein
Publikationsdatum: 05.06.2021
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 9/2021
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-021-01454-w

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer

Association between weight cycling and risk of kidney cancer: a prospective cohort study and meta-analysis of observational studies

Are care experiences associated with survival among cancer patients? An analysis of the SEER-CAHPS data resource

Long-term residential exposure to air pollution and Hodgkin lymphoma risk among adults in Denmark: a population-based case–control study

Disparities in HPV knowledge by race/ethnicity and socioeconomic position: Trusted sources for the dissemination of HPV information

Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie